SCHEMBL2149382

SCHEMBL2149382

COC(=O)/C=C/c1cccc(F)c1N

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
ALDH1A1 P00352 3/20 0.45
MAPT P10636 3/20 0.45
TP53 P04637 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP2C9 P11712 1/20 0.45
HPGD P15428 1/20 0.45
ALOX15 P16050 1/20 0.45
CYP2C19 P33261 1/20 0.45
HSD17B10 Q99714 1/20 0.45
MCL1 Q07820 1/20 0.44
MAOB P27338 2/20 0.43
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
TYR P14679 1/20 0.42
CA7 P43166 1/20 0.42
CA9 Q16790 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30578183 1.00 KDM4E (0.46) KDM4EMEN1KMT2AALDH1A1MAPT
SCHEMBL27647189 1.00 KDM4E (0.46) KDM4EMEN1KMT2AALDH1A1MAPT
SCHEMBL14930494 0.84 PTGS2 (0.54) KDM4EMEN1KMT2AALDH1A1MAPT
SCHEMBL149581 0.83 MAOB (0.59) KDM4EMEN1KMT2AALDH1A1MAPT
SCHEMBL29900779 0.83 MAOB (0.59) KDM4EMEN1KMT2AALDH1A1MAPT
SCHEMBL149579 0.83 MAOB (0.59) KDM4EMEN1KMT2AALDH1A1MAPT
SCHEMBL14257595 0.81 MCL1 (0.38) KDM4EMEN1KMT2AMAPTMCL1
SCHEMBL26969013 0.81 ALDH1A1 (0.45) KDM4EMEN1KMT2AALDH1A1MAPT
SCHEMBL15195165 0.81 NFE2L2 (0.54) KDM4EMEN1KMT2AALDH1A1MAPT
SCHEMBL5388848 0.80 CA1 (0.50) KDM4EALDH1A1MAPTMAOBCA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116874436-A Preparation method of letromycin intermediate 济宁学院 2023-10-13 CN claimed
US-RE49698-E1 Substituted dihydroquinazolines AIC246 AG & CO. KG (DE) 2023-10-17 US disclosed
US-RE49698-E1 Substituted dihydroquinazolines AIC246 AG & CO. KG (DE) 2023-10-17 US disclosed
CN-116874436-A Preparation method of letromycin intermediate 济宁学院 2023-10-13 CN disclosed
CN-116874436-A Preparation method of letromycin intermediate 济宁学院 2023-10-13 CN disclosed
EP-1622880-B3 SUBSTITUTED DIHYDROCHINAZOLINES HAVING ANTIVIRAL PROPERTIES AICURIS ANTI INFECTIVE CURES GMBH (DE) 2018-05-23 EP disclosed
EP-1622880-B3 SUBSTITUTED DIHYDROCHINAZOLINES HAVING ANTIVIRAL PROPERTIES AICURIS ANTI INFECTIVE CURES GMBH (DE) 2018-05-23 EP disclosed
US-RE46791-E1 Substituted dihydroquinazolines AICURIS ANTI-INFECTIVE CURES GMBH (DE) 2018-04-17 US disclosed
US-RE46791-E1 Substituted dihydroquinazolines AICURIS ANTI-INFECTIVE CURES GMBH (DE) 2018-04-17 US disclosed
US-9890128-B2 Process for making substituted quinazoline compounds MERCK SHARP & DOHME CORP. (US) 2018-02-13 US disclosed
EP-1622880-B1 SUBSTITUTED DIHYDROCHINAZOLINES HAVING ANTIVIRAL PROPERTIES BAYER HEALTHCARE AG (DE) 2007-02-28 EP disclosed
EP-1622880-B1 SUBSTITUTED DIHYDROCHINAZOLINES HAVING ANTIVIRAL PROPERTIES BAYER HEALTHCARE AG (DE) 2007-02-28 EP disclosed
EP-1685123-A2 SUBSTITUTED DIHYDROQUINAZOLINES II Bayer HealthCare AG (DE) 2006-08-02 EP disclosed
EP-1625129-A1 HETEROCYCLYL-SUBSTITUTED DIHYDROQUINAZOLINES AND USE THEREOF AS AN ANTIVIRAL AGENT Bayer HealthCare AG (DE) 2006-02-15 EP disclosed
EP-1622880-A1 SUBSTITUTED DIHYDROCHINAZOLINES HAVING ANTIVIRAL PROPERTIES Bayer HealthCare AG (DE) 2006-02-08 EP disclosed
EP-1562913-A1 SUBSTITUTED QUINAZOLINES AS ANTIVIRAL AGENTS, ESPECIALLY AGAINST CYTOMEGALOVIRUSES Bayer HealthCare AG (DE) 2005-08-17 EP disclosed
WO-2005047278-A2 SUBSTITUTED DIHYDROQUINAZOLINES II BAYER HEALTHCARE AG (DE) 2005-05-26 WO disclosed
WO-2004099212-A1 HETEROCYCLYL-SUBSTITUTED DIHYDROQUINAZOLINES AND USE THEREOF AS AN ANTIVIRAL AGENT BAYER HEALTHCARE AG (DE) 2004-11-18 WO disclosed
WO-2004096778-A1 SUBSTITUTED DIHYDROCHINAZOLINES HAVING ANTIVIRAL PROPERTIES BAYER HEALTHCARE AG (DE) 2004-11-11 WO disclosed
WO-2004041790-A1 SUBSTITUTED QUINAZOLINES AS ANTIVIRAL AGENTS, ESPECIALLY AGAINST CYTOMEGALOVIRUSES BAYER HEALTHCARE AG (DE) 2004-05-21 WO disclosed